Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer

Purpose Cyclin D/cyclin-dependent kinase 4/6 (CDK4/6) complex inhibitors have recently been proven effective when combined with endocrine therapy in clinical trials. However, the clinical benefit from CDK4/6 inhibitor varied from different patients. In order to optimize the clinical application of C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2018-04, Vol.168 (2), p.287-297
Hauptverfasser:	Fang, Hehui, Huang, Doudou, Yang, Fang, Guan, Xiaoxiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiestrogens Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological markers Biomarkers Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer research Clinical trials Clinical Trials as Topic Cyclin D Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-dependent kinases Endocrine therapy Estrogen receptors Estrogens Female Hormones Humans Medicine Medicine & Public Health Molecular Targeted Therapy - methods Oncology Patient Selection Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Receptors, Estrogen - antagonists & inhibitors Receptors, Estrogen - metabolism Review Subpopulations Therapeutics Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!